These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 25716902)

  • 1. The choice of the noninferiority margin in clinical trials was driven by baseline risk, type of primary outcome, and benefits of new treatment.
    Gayet-Ageron A; Agoritsas T; Rudaz S; Courvoisier D; Perneger T
    J Clin Epidemiol; 2015 Oct; 68(10):1144-51. PubMed ID: 25716902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How do researchers determine the difference to be detected in superiority trials? Results of a survey from a panel of researchers.
    Gayet-Ageron A; Jannot AS; Agoritsas T; Rudaz S; Combescure C; Perneger T
    BMC Med Res Methodol; 2016 Jul; 16():89. PubMed ID: 27473336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E; Tango T
    J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of delta noninferiority margin and dependency of the noninferiority trials.
    Tsong Y; Zhang J; Levenson M
    J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What differences are detected by superiority trials or ruled out by noninferiority trials? A cross-sectional study on a random sample of two-hundred two-arms parallel group randomized clinical trials.
    Gayet-Ageron A; Agoritsas T; Combescure C; Bagamery K; Courvoisier DS; Perneger TV
    BMC Med Res Methodol; 2010 Oct; 10():93. PubMed ID: 20950464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninferiority trials with nonadherence to the assigned randomized treatment.
    Korn EL; Gray RJ; Freidlin B
    Clin Trials; 2019 Dec; 16(6):673-681. PubMed ID: 31409130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninferiority testing beyond simple two-sample comparison.
    Tsong Y; Chen WJ
    J Biopharm Stat; 2007; 17(2):289-308. PubMed ID: 17365225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bootstrap-based test for establishing noninferiority in clinical trials.
    Chen M; Kianifard F; Dhar SK
    J Biopharm Stat; 2006 May; 16(3):357-63. PubMed ID: 16724490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio.
    Hida E; Tango T
    Pharm Stat; 2018 Sep; 17(5):489-503. PubMed ID: 29984524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators.
    Leon AC
    J Clin Psychiatry; 2011 Oct; 72(10):1344-9. PubMed ID: 21367350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting of noninferiority trials was incomplete in trial registries.
    Dekkers OM; Soonawala D; Vandenbroucke JP; Egger M
    J Clin Epidemiol; 2011 Sep; 64(9):1034-8. PubMed ID: 21444195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial design for assessing noninferiority when superiority is expected.
    Freidlin B; Korn EL; George SL; Gray R
    J Clin Oncol; 2007 Nov; 25(31):5019-23. PubMed ID: 17971602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninferiority trial designs for odds ratios and risk differences.
    Hilton JF
    Stat Med; 2010 Apr; 29(9):982-93. PubMed ID: 20191595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting.
    Dekkers OM; Cevallos M; Bührer J; Poncet A; Ackermann Rau S; Perneger TV; Egger M
    J Clin Epidemiol; 2015 May; 68(5):510-7. PubMed ID: 25450451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justification of noninferiority margin: methodology considerations in an exposure-response analysis.
    Wang Y; Harigaya Y; Cavaillé-Coll M; Colangelo P; Reynolds KS
    Clin Pharmacol Ther; 2015 Apr; 97(4):404-10. PubMed ID: 25670256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality.
    Gomberg-Maitland M; Frison L; Halperin JL
    Am Heart J; 2003 Sep; 146(3):398-403. PubMed ID: 12947355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the three-arm non-inferiority trial including a placebo with a prespecified margin.
    Hida E; Tango T
    Stat Med; 2011 Feb; 30(3):224-31. PubMed ID: 21213340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.